GATA6 Deficiency Leads to Epithelial Barrier Dysfunction and Enhances Susceptibility to Gut Inflammation.


Journal

Journal of Crohn's & colitis
ISSN: 1876-4479
Titre abrégé: J Crohns Colitis
Pays: England
ID NLM: 101318676

Informations de publication

Date de publication:
23 Feb 2022
Historique:
pubmed: 11 8 2021
medline: 25 2 2022
entrez: 10 8 2021
Statut: ppublish

Résumé

Intestinal barrier dysfunction is a hallmark of inflammatory bowel diseases [IBD], but the mechanisms that lead to such a defect are not fully understood. This study was aimed at characterising the factors involved in the defective barrier function in IBD. Transcriptome analysis was performed on colon samples taken from healthy controls [CTR] and IBD patients. Expression of GATA-binding factor 6 [GATA6], a transcription factor involved in intestinal epithelial cell differentiation, was evaluated in colon samples taken from CTR and IBD patients by real-time polymerase chain reaction [PCR] and immunohistochemistry. Intestinal sections of wild-type and Gata6del mice, which exhibit a conditional Gata6 deletion in intestinal epithelial cells and which are either left untreated or receive subcutaneous indomethacin or rectal trinitrobenzene sulphonic acid, were stained with haematoxylin and eosin. In parallel, some Gata6del mice received antibiotics to deplete intestinal flora. Mucosal inflammatory cell infiltration and cytokine production were evaluated by flow cytometry and real-time PCR, respectively, and tight junction proteins were examined by immunofluorescence. Intestinal barrier integrity was assessed by fluorescein isothiocyanate [FITC]-dextran assay. Multiple genes involved in cell commitment/proliferation and wound healing were differentially expressed in IBD compared with CTR. Among these, GATA6 was significantly decreased in the IBD epithelium compared with CTR. In mice, conditional deletion of GATA6 in the intestinal epithelium induced primarily epithelial damage, diminished zonula occludens-1 expression, and enhanced intestinal permeability, ultimately resulting in bacteria-driven local immune response and enhanced susceptibility to gut inflammation. Reduced expression of GATA6 promotes intestinal barrier dysfunction, thus amplifying intestinal inflammatory pathology.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
Intestinal barrier dysfunction is a hallmark of inflammatory bowel diseases [IBD], but the mechanisms that lead to such a defect are not fully understood. This study was aimed at characterising the factors involved in the defective barrier function in IBD.
METHODS METHODS
Transcriptome analysis was performed on colon samples taken from healthy controls [CTR] and IBD patients. Expression of GATA-binding factor 6 [GATA6], a transcription factor involved in intestinal epithelial cell differentiation, was evaluated in colon samples taken from CTR and IBD patients by real-time polymerase chain reaction [PCR] and immunohistochemistry. Intestinal sections of wild-type and Gata6del mice, which exhibit a conditional Gata6 deletion in intestinal epithelial cells and which are either left untreated or receive subcutaneous indomethacin or rectal trinitrobenzene sulphonic acid, were stained with haematoxylin and eosin. In parallel, some Gata6del mice received antibiotics to deplete intestinal flora. Mucosal inflammatory cell infiltration and cytokine production were evaluated by flow cytometry and real-time PCR, respectively, and tight junction proteins were examined by immunofluorescence. Intestinal barrier integrity was assessed by fluorescein isothiocyanate [FITC]-dextran assay.
RESULTS RESULTS
Multiple genes involved in cell commitment/proliferation and wound healing were differentially expressed in IBD compared with CTR. Among these, GATA6 was significantly decreased in the IBD epithelium compared with CTR. In mice, conditional deletion of GATA6 in the intestinal epithelium induced primarily epithelial damage, diminished zonula occludens-1 expression, and enhanced intestinal permeability, ultimately resulting in bacteria-driven local immune response and enhanced susceptibility to gut inflammation.
CONCLUSIONS CONCLUSIONS
Reduced expression of GATA6 promotes intestinal barrier dysfunction, thus amplifying intestinal inflammatory pathology.

Identifiants

pubmed: 34374415
pii: 6347240
doi: 10.1093/ecco-jcc/jjab145
doi:

Substances chimiques

GATA6 Transcription Factor 0
GATA6 protein, human 0
Gata6 protein, mouse 0
Dextran Sulfate 9042-14-2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

301-311

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Federica Laudisi (F)

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

Carmine Stolfi (C)

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Division of Clinical Biochemistry and Clinical Molecular Biology, University of Rome Tor Vergata, Rome, Italy.

Gerolamo Bevivino (G)

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

Claudia Maresca (C)

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

Eleonora Franzè (E)

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

Edoardo Troncone (E)

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

Elisabetta Lolli (E)

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

Irene Marafini (I)

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

Daniele Pietrucci (D)

Department of Biology, University of Rome Tor Vergata, Rome, Italy.
Department for Innovation in Biological, Agro-Food and Forest Systems, DIBAF, University of Tuscia, Viterbo, Italy.

Adelaide Teofani (A)

Department of Biology, University of Rome Tor Vergata, Rome, Italy.

Antonio Di Grazia (A)

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

Davide Di Fusco (D)

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

Alfredo Colantoni (A)

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

Angela Ortenzi (A)

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

Alessandro Desideri (A)

Department of Biology, University of Rome Tor Vergata, Rome, Italy.

Ivan Monteleone (I)

Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.

Giovanni Monteleone (G)

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH